tbuckley/cabot-search huggingface dataset:
The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories
Authors: Alexander Kohlmann, Giovanni Martinelli, Mary Alikian, Valentina Artusi, Bernd Auber, Monika Belickova, Ilaria Bronzini, Giovanni Cazzaniga, Sabina Chiaretti, Thomas Ernst, Marc Fuellgrabe, Christian Gabriel, Jesus Hernandez, Joop H. Jansen, Ilaria Iacobucci, Thomas Lion, Laurence Lode, Joaquin Martinez-Lopez, Ken I. Mills, Maximilian Mossner, Katerina Machova Polakova, Naomi A. Porret, Sarka Pospisilova, Claude Preudhomme, Muge Sayitoglu, Simona Soverini, Orietta Spinelli, Christian Thiede, Peter Vandenberghe, Juh Eng Yeoh, Andreas Hochhaus, Torsten Haferlach
Journal: Blood (2013)
First evaluation of QuantiFERON-TB Gold Plus performance in contact screening
Authors: Lucia Barcellini, Emanuele Borroni, James Brown, Enrico Brunetti, Daniela Campisi, Paola F. Castellotti, Luigi R. Codecasa, Federica Cugnata, Clelia Di Serio, Maurizio Ferrarese, Delia Goletti, Marc Lipman, Paola M.V. Rancoita, Giulia Russo, Marina Tadolini, Elisa Vanino, Daniela M. Cirillo
Journal: European Respiratory Journal (2016)

Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of interferon-γ release assay, QuantiFERON-TB Plus (QFT-Plus), which includes an additional antigen tube (TB2), stimulating both CD4+ and CD8+ T-cells in contacts of TB patients.Contacts were screened for latent TB infection by tuberculin skin test, QFT-Plus and QuantiFERON-TB Gold in Tube (QFT-GIT).In 119 TB contacts, the overall agreement between QFT-Plus and QFT-GIT was high, with a Cohen's κ of 0.8. Discordant results were found in 12 subjects with negative QFT-GIT and positive QFT-Plus results. In analyses of markers of TB exposure and test results, the average time spent with the index case was the strongest risk factor for positivity in each of these tests. The difference in interferon-γ production between the two antigen tubes (TB2-TB1) was used as an estimate of CD8+ stimulation provided by the TB2. TB2-TB1 values >0.6 IU·mL-1 were significantly associated with proximity to the index case and European origin.QFT-Plus has a stronger association with surrogate measures of TB exposure than QFT-GIT in adults screened for latent TB infection. Interferon-γ response in the new antigen tube used an indirect estimate of specific CD8+ response correlates with increased Mycobacterium tuberculosis exposure, suggesting a possible role in identifying individuals with recent infection.
In older hospitalized patients, adding transitional care to in-hospital geriatric assessment did not improve ADL
Authors: Fitzhugh C. Pannill
Journal: Annals of Internal Medicine (2016)

Source Citation Buurman BM, Parlevliet JL, Allore HG, et al. Comprehensive geriatric assessment and transitional care in acutely hospitalized patients: the transitional care bridge randomized clinical trial. JAMA Intern Med. 2016;176:302-9. 26882111
978-62 The Magnitude of Myocardial Dysfunction is Greater in Painful than in Painless Myocardial Ischaemia. An Exercise Echocardlographic Study
Authors: Petros Nihoyannopoulos, Antonis Marsonis, Jayshree Joshi, George Athanassopoulos, Celia M. Oakley
Journal: Journal of the American College of Cardiology (1995)
Dense red blood cell and oxygen desaturation in sickle‐cell disease
Authors: Gaetana Di Liberto, Laurent Kiger, Michael C. Marden, Laurent Boyer, Florence Canoui Poitrine, Marc Conti, Marie Georgine Rakotoson, Anoosha Habibi, Sanam Khorgami, Benoit Vingert, Bernard Maitre, Frederic Galacteros, France Pirenne, Pablo Bartolucci
Journal: American Journal of Hematology (2016)

Production of abnormal hemoglobin (HbS) in sickle-cell disease (SCD) results in its polymerization in deoxygenated conditions and in sickled-RBC formation. Dense RBCs (DRBCs), defined as density >1.11 and characterized by increased rigidity are absent in normal AA subjects, but present at percentages that vary of a patient to another remaining stable throughout adulthood for each patient. Polymerized HbS has reduced affinity for oxygen, demonstrated by the rightward shift of the oxygen-dissociation curve, leading to disturbances in oxygen transport. Ninety-two SCD patients' total RBCs were separated into LightDRBC (LRBC) (d < 1.11 g/mL) and DRBC fractions. Venous blood partial oxygen pressure and RBC-fraction-deoxygenation and -reoxygenation Hb-oxygen-equilibrium curves were determined. All patients took a 6-minute walking test (6MWT); 10 had results before and after >6 months on hydroxyurea. 6MWT time with SpO2 < 88% (TSpO2 < 88) assessed the physiological impact of exertion. Elevated mean corpuscular hemoglobin (Hb) concentrations, decreased %HbF, and 2,3-bisphosphoglycerates in DRBCs modulated Hb-oxygen affinity. Deoxygenation and reoxygenation Hb-oxygen equilibrium curves differed between normal Hb AA and SS RBCs and between LRBCs and DRBCs, with rightward shifts confirming HbS-polymerization's role in affinity loss. In bivariate analyses, 50% Hb saturation correlated positively with %DRBCs (P < 0.0001, r(2) = 0.34) and negatively with %HbF (P < 0.0001, r(2) = 0.25). The higher the %DRBCs, the longer the TSpO2 88 (P = 0.04). Hydroxyurea was associated with significantly shorter TSpO2 < 88 (P = 0.01). We report that the %DRBCs directly affects SCD patients' SpO2 during exertion; hydroxyurea improves oxygen affinity and lowers the %DRBCs. Am. J. Hematol. 91:1008-1013, 2016. © 2016 Wiley Periodicals, Inc.
Unusual aetiology of a hilar mass in a man with history of thyroid cancer
Authors: Macarena R Vial, John Stewart, Donald R Lazarus, George A Eapen, David E Ost, Horiana B Grosu, Carlos A Jimenez
Journal: Thorax (2016)

A 39-year-old male non-smoking lumberyard worker from northern Mississippi was referred for evaluation of a left lower lobe mass. He had been treated 4 years earlier for papillary thyroid cancer with thyroidectomy and radioactive iodine ablation. Neck dissection after treatment showed 5/54 nodes with metastases and 3 nodes with granulomatous inflammation. He had been followed without evidence of recurrent malignancy until a CT obtained during a respiratory infection showed a left lower lobe mass extending to the hilum …
Asbestos as Modern Urban Hazard
Authors: J G THOMSON, R O KASCHULA, R R MACDONALD
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fish Intake During Pregnancy and Offspring Adiposity
Authors: Natalie K. Hyde, Sharon L. Brennan-Olsen, Julie A. Pasco
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
New GPs are offered £20 000 to work in underserved areas
Authors: Adrian O’Dowd
Journal: BMJ (2016)

Trainee GPs are being offered £20 000 (€26 000; $29 000) bursaries to work in certain parts of England that don’t have enough doctors and have found it hard to recruit people for the past three years.

The new Targeted Enhanced Recruitment Scheme (https://gprecruitment.hee.nhs.uk/Recruitment/TERS) launched by NHS England and run by Health Education England is offering the one-off bursary to GP trainees who commit themselves to working in one of 109 training places in England.

The BMA, although supporting the scheme, said that it was only one way to tackle serious recruitment problems in general practice and that even bigger incentives might be needed, such as paying off part of student loans for trainees considering general practice.

Under the scheme, the bursary is paid as a lump sum when the doctor starts the training post and will be administered by the local HEE office where the appointment is based. …
Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy
Authors: Gabriel Etienne, Nicolini E Nicolini, Stéphanie Dulucq, Anna Schmitt, Sandrine Hayette, Éric Lippert, Isabelle Tigaud, Stephane Morisset, Caroline Bureau, Didier Adiko, Gerald Marit, Josy Reiffers, Francois-Xavier Mahon
Journal: Blood (2012)
Professing the Values of Medicine
Authors: Stephen Brotherton, Audiey Kao, B. J. Crigger
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lung Cancer Symptom Scale (LCSS) as a marker of treatment (tx) benefit with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC from CheckMate 057.
Authors: Richard J. Gralla, David R. Spigel, Bryan Bennett, Fiona Taylor, John R. Penrod, Michael DeRosa, Homa Dastani, Lucinda Strycker Orsini, Martin Reck
Journal: Journal of Clinical Oncology (2016)

9031 Background: Nivo is the first anti–programmed death-1 agent to demonstrate a survival benefit vs doc in pts with previously treated adv NSQ and SQ NSCLC. Here we report the impact of nivo vs doc on disease-related symptoms in pts with adv NSQ NSCLC from the CheckMate 057 study. Methods: LCSS was assessed every other cycle (Q4W) for nivo and every cycle (Q3W) for doc for the first 6 mo on tx, then every 6 wks and at 2 post-tx follow-up visits. LCSS includes the average symptom burden index (ASBI; based on 6 symptoms: anorexia, fatigue, cough, dyspnea, hemoptysis, and pain) and the 3-item global index (3-IGI; symptom distress, interference with activities, and health-related quality of life [HRQoL]). LCSS changes from baseline (BL) and time to first deterioration (TTD) in symptoms were estimated. Results: Analyses of mean changes from BL in the LCSS ASBI and 3-IGI indicated numerical differences favoring nivo vs doc emerging at the first common assessment (wk 12) and persisting throughout the entire assessment period. At common assessments with > 10 pts in each arm (to wk 48), the differences were significant (CIs excluding no difference) for the ASBI at wks 12, 24, 30, and 42, and for the 3-IGI at wks 24 and 30. Five of 6 symptoms (including pain and fatigue) and 2 of 3 items of the 3-IGI (HRQoL and symptom distress) had significant differences favoring nivo at ≥ 1 common assessments. TTD (based on the minimally important difference [MID]) was longer with nivo vs doc for the ASBI (HR = 0.65; 95% CI: 0.49, 0.85) and 3-IGI (HR = 0.63; 95% CI: 0.48, 0.82), with Kaplan-Meier curves between tx arms separating at ≈2 months. TTD for individual symptoms within the ASBI and individual items of the 3-IGI showed a similar pattern. The proportion of pts with improvement in the LCSS ASBI greater than the MID by wk 12 was similar for nivo (17.8%; 95% CI: 13.6, 22.7) and doc (19.7%; 95% CI: 15.2, 24.7). Conclusions: These results from this large, phase III study indicate that pts with previously treated adv NSQ NSCLC had significantly better symptom burden outcomes and HRQoL while on tx with nivo vs doc. TTD was significantly longer in nivo- vs doc-treated pts. Clinical trial information: NCT01673867.
Minimizing toxicity of MACOP-B.
Authors: J M Connors, P Klimo
Journal: Journal of Clinical Oncology (1987)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1987.5.8.1302 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2442319 Minimizing toxicity of MACOP-B. J M ConnorsxJ M ConnorsSearch for articles by this author , P KlimoxP KlimoSearch for articles by this author https://doi.org/10.1200/JCO.1987.5.8.1302 PDF "Minimizing toxicity of MACOP-B.." Journal of Clinical Oncology, 5(8), pp. 1302–1303© 1987 by American Society of Clinical Oncology
Racial/Ethnic Disparities in Genomic Sequencing
Authors: Daniel E. Spratt, Tiffany Chan, Levi Waldron, Corey Speers, Felix Y. Feng, Olorunseun O. Ogunwobi, Joseph R. Osborne
Journal: JAMA Oncology (2016)

<h3>Importance</h3> Although poorly understood, there is heterogeneity in the molecular biology of cancer across race and ethnicities. The representation of racial minorities in large genomic sequencing efforts is unclear, and could have an impact on health care disparities. <h3>Objective</h3> To determine the racial distribution among samples sequenced within The Cancer Genome Atlas (TCGA) and the deficit of samples needed to detect moderately common mutational frequencies in racial minorities. <h3>Design, Setting, and Participants</h3> This was a retrospective review of individual patient data from TCGA data portal accessed in July 2015. TCGA comprises samples from a wide array of institutions primarily across the United States. Samples from 10 of the 31 currently available tumor types were analyzed, comprising 5729 samples from the approximately 11 000 available. <h3>Main Outcomes and Measures</h3> Using the estimated median somatic mutational frequency, the samples needed beyond TCGA to detect a 10% and 5% mutational frequency over the background somatic mutation frequency were calculated for each tumor type by racial ethnicity. <h3>Results</h3> Of the 5729 samples, 77% (n = 4389) were white, 12% (n = 660) were black, 3% (n = 173) were Asian, 3% (n = 149) were Hispanic, and less than 0.5% combined were from patients of Native Hawaiian, Pacific Islander, Alaskan Native, or American Indian decent. This overrepresents white patients compared with the US population and underrepresents primarily Asian and Hispanic patients. With a somatic mutational frequency of 0.7 (prostate cancer) to 9.9 (lung squamous cell cancer), all tumor types from white patients contained enough samples to detect a 10% mutational frequency. This is in contrast to all other racial ethnicities, for which group-specific mutations with 10% frequency would be detectable only for black patients with breast cancer. Group-specific mutations with 5% frequency would be undetectable in any racial minority, but detectable in white patients for all cancer types except lung (adenocarcinoma and squamous cell carcinoma) and colon cancer. <h3>Conclusions and Relevance</h3> It is probable, but poorly understood, that ethnic diversity is related to the pathogenesis of cancer, and may have an impact on the generalizability of findings from TCGA to racial minorities. Despite the important benefits that continue to be gained from genomic sequencing, dedicated efforts are needed to avoid widening the already pervasive gap in health care disparities.
Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7.
Authors: Debu Tripathy, Aditya Bardia, Sara A. Hurvitz, Nadia Harbeck, Marco Colleoni, Fabio A. Franke, Louis W.C. Chow, Seock-Ah Im, Zhimin Shao, John R. Keyserlingk, Lidia Mongay Soler, Melissa Horan, Shyeilla V. Dhuria, Gareth Hughes, Yen-Shen Lu
Journal: Journal of Clinical Oncology (2015)

TPS625 Background: Tamoxifen or NSAIs with ovarian function suppression are standard first-line endocrine therapy (ET) options for premenopausal women with HR+, HER2– aBC; however resistance eventually occurs. The cyclin D–cyclin dependent kinase (CDK)4/6–INK4–Rb pathway is frequently dysregulated in HR+ BC; preclinical data suggest that CDK4/6 inhibition may abrogate endocrine-resistant cell proliferation in BC subsets. Adding ribociclib, a highly selective CDK4/6 inhibitor, to standard ET may provide therapeutic benefit vs ET alone in HR+, HER2– aBC. Methods: A Ph III, randomized, double-blind, placebo-controlled study of continuous tamoxifen (20 mg once daily [QD]) or NSAI (letrozole [2.5 mg QD] or anastrozole [1 mg QD]), with subcutaneous goserelin implant (3.6 mg D1 of each 28-day cycle) and ribociclib (600 mg QD, D1–21 of each 28-day cycle) or matching placebo (MONALEESA-7; NCT02278120). Key inclusion criteria: pre- or perimenopausal women with ER+ and/or PR+, HER2– aBC; ECOG PS ≤ 1. Patients that h...
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping
Authors: Rebecca S. Heist, Lecia V. Sequist, Darrell Borger, Justin F. Gainor, Ronald S. Arellano, Long P. Le, Dora Dias-Santagata, Jeffrey W. Clark, Jeffrey A. Engelman, Alice T. Shaw, A. John Iafrate
Journal: Journal of Thoracic Oncology (2016)
Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs
Authors: Sundar Jagannath, Anuja Roy, Jonathan K Kish, Denise Globe, Orsolya Lunacsek, Michael T. Eaddy, Emil T Kuriakose, Joanne Willey, David Siegel
Journal: Blood (2015)
Waterborne outbreak among Spanish tourists in a holiday resort in the Dominican Republic, August 2002
Authors: A Paez Jimenez, R Pimentel, M V Martinez de Aragon, G Hernández Pezzi, S Mateo, J. F. Martinez Navarro
Journal: Eurosurveillance (2004)

On 3 September 2002, the Spanish national centre of epidemiology (Centro Nacional de Epidemiologia--CNE) was alerted to a high number of gastroenteritis cases in Spanish tourists who had travelled to a hotel in Punta Cana on different days during august 2002. Entamoeba hystolitica cysts have been visualised by microscopy in the stools of several patients that sought medical attention in the Dominican Republic. The CNE informed the health authorities in the Dominican Republic and conducted in conjunction an epidemiological investigation. A descriptive study of the 76 initial cases estimated a mean illness duration of 5.1+2.9 days and a exposure period of 3.6+2.2 days. Following a retrospective cohort study, the attack rate was found to be 32.4%. Consequently, 216 (95% CI=114.75-317.25) spanish tourists had probably developed the illness. Stool samples were collected in Spain from untreated patients who still felt unwell. None of the samples were positive for E.hystolitica. On 10 September, a hygiene inspection was undertaken at the hotel. Samples of the ice and meals served at the buffet that day, yielded coliform bacteria. Consumption of water from the resort water system was the only risk factor associated with the symptoms (RR= 3.55; 95% CI =1.13-10.99). To avoid similar outbreaks occurring again at the hotel, it is essential to regularly monitor the water quality and to improve food handling hygiene standards. Basic food hygiene training for food handlers should be mandatory. An international guideline for the management foodborne and waterborne outbreaks among tourists in holiday resorts should be drawn up, involving all competent authorities of both destination and tourist origin countries.
New Appliances
Authors: E D VERE NICOLL
Journal: BMJ (1962)

Department of Preventive Medicine) discussed the role of the doctor in community health.He was followed by Dr. A. M. M. WILSON (Department of Microbiology), who described the prevalence and distribution of brucellosis in Uganda.Dr. Wilson considered the low record of prevalence in the past to be a false picture which was probably due to the lack of the laboratory facilities necessary to prove the diagnosis.Dr.
RM-063 Neoadjuvant chemotherapy for unresectable carcinoma gall bladder: our experience
Authors: S. Bhoriwal, M. Sultania, S. Kumar, S.V.S. Deo, N. Shukla, D. Pandey, A. Sharma, R. Sahoo, S. Pathy, S. Thulkar, M. Pathak
Journal: Annals of Oncology (2016)
A Technique for Endo-Organ Resection of Gastric Wall Tumors Using One Intragastric Trocar
Authors: M.  Pross, S.  Wolff, G.  Nestler, D.  Schubert, S.  Kahl, H.  Lippert
Journal: Endoscopy (2003)

This report describes a new technique for combined laparoscopic and gastroscopic intragastric resection of benign gastric wall tumors. We performed this combined endo-organ procedure in five patients. Endo-organ intragastric resection is only used with posterior gastric wall tumors and tumors located near the cardia and the pylorus. For this approach, only one trocar is placed into the stomach for intragastric introduction of the endostapler. The video gastroscope allows intragastric vision. We recommend our procedure for the extirpation of small, benign, intramural gastric tumors, as a safe and very comfortable method for the patient.